Lloyd T. Lam

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler et al. · Nature Medicine · 2013 · 2.9K citations

Thrombopoiesis, Thrombosis, Hematological Malignancy +11

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

Georg Lenz, George W. Wright, N. C. Tolga Emre et al. · Proceedings of the National Academy of Sciences · 2008 · 973 citations · Full text

Molecular Diagnosis of Burkitt's Lymphoma

Sandeep S. Davé, Kai Fu, George W. Wright et al. · New England Journal of Medicine · 2006 · 902 citations · Full text

Oncogenic <i>CARD11</i> Mutations in Human Diffuse Large B Cell Lymphoma

Georg Lenz, R. Eric Davis, Vu N. Ngo et al. · Science · 2008 · 869 citations

Hematological Malignancy, Tumor Biology, Lymphoid Neoplasia +14

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Loren Lasko, Clarissa G. Jakob, Rohinton Edalji et al. · Nature · 2017 · 813 citations · Full text

Lineage-specific Tumours, Medicine, Immune Checkpoint Inhibitor +8